Risk stratification and prognostic evaluation of endothelial cell‑specific molecule1, von Willebrand factor, and a disintegrin‑like and metalloprotease with thrombospondin type 1 motif for sepsis in the emergency department: An observational study

Zhang,Qing; Li,Chun‑Sheng

doi:10.3892/etm.2019.7485

Risk stratification and prognostic evaluation of endothelial cell‑specific molecule1, von Willebrand factor, and a disintegrin‑like and metalloprotease with thrombospondin type 1 motif for sepsis in the emergency department: An observational study

Authors:
- Qing Zhang
- Chun‑Sheng Li
View Affiliations

Affiliations: Department of Emergency, Beijing Chao‑Yang Hospital, Capital Medical University, Beijing 100020, P.R. China, Beijing Key Laboratory of Cardiopulmonary Cerebral Resuscitation, Beijing 100020, P.R. China
Published online on: April 15, 2019 https://doi.org/10.3892/etm.2019.7485
Pages: 4527-4535
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study evaluated endothelial cell‑specific molecule1 (endocan), von Willebrand factor (vWF), and A disintegrin‑like and metalloprotease with thrombospondin type 1 motif (ADAMTS‑13), alone or in combination, in the risk stratification and prognosis prediction of patients with sepsis. Clinical data of 301 patients were prospectively analyzed, and divided into systemic inflammatory reaction syndrome, sepsis, severe sepsis, and septic shock groups. A total of 40 healthy individuals were studied as the control group. Endocan, vWF, ADAMTS‑13, vWF/ADAMTS‑13, and procalcitonin levels were measured, and Acute Physiology and Chronic Health Evaluation (APACHE II) score, Mortality in Emergency Department Sepsis (MEDS) score as well as Sequential Organ Failure Assessment (SOFA) score were calculated. The all‑cause death or survival of each patient was recorded during the 28-day follow‑up. The endocan, vWF, and vWF/ADAMTS‑13 levels significantly increased in patients and were positively correlated with disease severity. On the first day of admission, MEDS score, ADAMTS‑13, and vWF/AMAMTS‑13 ratio were independent predictors for 28-day mortality from sepsis. Moreover, the combination of vWF/ADAMTS‑13 ratio with MEDS score improved the accuracy in predicting the 28-day mortality from sepsis. On day 5, endocan, vWF, ADAMTS‑13, and vWF/ADAMTS‑13 ratio were independent predictors for the 28-day mortality from sepsis, while the combined use of endocan and vWF/ADAMTS‑13 ratio improved the prognostic value of individual indicators. Endocan, vWF, ADAMTS‑13, and vWF/ADAMTS‑13 ratio are valuable in the risk stratification and prognostic evaluation of sepsis as novel biomarkers.

View Figures

View References

1	Lever A and Mackenzie I: Sepsis: Definition, epidemiology, and diagnosis. BMJ. 335:879–883. 2007. View Article : Google Scholar : PubMed/NCBI
2	Zambon M, Ceola M, Almeida-de-Castro R, Gullo A and Vincent JL: Implementation of the surviving sepsis campaign guidelines for severe sepsis and septic shock: We could go faster. J Crit Care. 23:455–460. 2008. View Article : Google Scholar : PubMed/NCBI
3	Pierrakos C and Vincent JL: Sepsis biomarkers: A review. Crit Care. 14:R152010. View Article : Google Scholar : PubMed/NCBI
4	Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL and Ramsay G; SCCM/ESICM/ACCP/ATS/SIS, : 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 31:1250–1256. 2003. View Article : Google Scholar : PubMed/NCBI
5	Knaus WA, Draper EA, Wagner DP and Zimmerman JE: APACHE II: A severity of disease classification system. Crit Care Med. 13:818–829. 1985. View Article : Google Scholar : PubMed/NCBI
6	Shapiro NI, Wolfe RE, Moore RB, Smith E, Burdick E and Bates DW: Mortality in Emergency Department Sepsis (MEDS) score: a prospectively derived and validated clinical prediction rule. Crit Care Med. 31:670–675. 2003. View Article : Google Scholar : PubMed/NCBI
7	Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM and Thijs LG: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine. Intensive Care Med. 22:707–710. 1996. View Article : Google Scholar : PubMed/NCBI
8	Shirakawa K, Naitou K, Hirose J, Takahashi T and Furusako S: Presepsin (sCD14-ST): Development and evaluation of one-step ELISA with a new standard that is similar to the form of presepsin in septic patients. Clin Chem Lab Med. 49:937–939. 2011. View Article : Google Scholar : PubMed/NCBI
9	Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, Sicignano A, Palazzo M, Moreno R, Boulmé R, et al: Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med. 28:108–121. 2002. View Article : Google Scholar : PubMed/NCBI
10	Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR and Payen D; Sepsis occurrence in acutely Ill patients investigators, : Sepsis in European intensive care units: Results of the SOAP study. Crit Care Med. 34:344–353. 2006. View Article : Google Scholar : PubMed/NCBI
11	Esteban A, Frutos-Vivar F, Ferguson ND, Peñuelas O, Lorente JA, Gordo F, Honrubia T, Algora A, Bustos A, García G, et al: Sepsis incidence and outcome: Contrasting the intensive care unit with the hospital ward. Crit Care Med. 35:1284–1289. 2007. View Article : Google Scholar : PubMed/NCBI
12	Gonsalves MD and Sakr Y: Early identification of sepsis. Curr Infect Dis Rep. 12:329–335. 2010. View Article : Google Scholar : PubMed/NCBI
13	Bauer M and Reinhart K: Molecular diagnostics of sepsis - where are we today? Int J Med Microbiol. 300:411–413. 2010. View Article : Google Scholar : PubMed/NCBI
14	Levy MM: Preface biomarkers in critical illness. Crit Care Clin. 27:xiii–xv. 2011. View Article : Google Scholar : PubMed/NCBI
15	Bongers TN, de Maat MP, van Goor ML, Bhagwanbali V, van Vliet HH, Gómez García EB, Dippel DW and Leebeek FW: High von Willebrand factor levels increase the risk of first ischemic stroke: Influence of ADAMTS13, inflammation, and genetic variability. Stroke. 37:2672–2677. 2006. View Article : Google Scholar : PubMed/NCBI
16	Nguyen TC, Liu A, Liu L, Ball C, Choi H, May WS, Aboulfatova K, Bergeron AL and Dong JF: Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Haematologica. 92:121–124. 2007. View Article : Google Scholar : PubMed/NCBI
17	Claus RA, Bockmeyer CL, Budde U, Kentouche K, Sossdorf M, Hilberg T, Schneppenheim R, Reinhart K, Bauer M, Brunkhorst FM, et al: Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure. Thromb Haemost. 101:239–247. 2009. View Article : Google Scholar : PubMed/NCBI
18	Scherpereel A, Depontieu F, Grigoriu B, Cavestri B, Tsicopoulos A, Gentina T, Jourdain M, Pugin J, Tonnel AB and Lassalle P: Endocan, a new endothelial marker in human sepsis. Crit Care Med. 34:532–537. 2006. View Article : Google Scholar : PubMed/NCBI
19	Chng WJ, Yip CY, Baliwag MB and Liu TC: Differential effect of the ABO blood group on von Willebrand factor collagen binding activity and ristocetin cofactor assay. Blood Coagul Fibrinolysis. 16:75–78. 2005. View Article : Google Scholar : PubMed/NCBI
20	Sadler JE: Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 67:395–424. 1998. View Article : Google Scholar : PubMed/NCBI
21	van Mourik JA, Boertjes R, Huisveld IA, Fijnvandraat K, Pajkrt D, van Genderen PJ and Fijnheer R: von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation. Blood. 94:179–185. 1999.PubMed/NCBI
22	Lerolle N, Dunois-Lardé C, Badirou I, Motto DG, Hill G, Bruneval P, Diehl JL, Denis CV and Baruch D: von Willebrand factor is a major determinant of ADAMTS-13 decrease during mouse sepsis induced by cecum ligation and puncture. J Thromb Haemost. 7:843–850. 2009. View Article : Google Scholar : PubMed/NCBI
23	Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, Schade AJ, McIntire LV, Fujikawa K and López JA: ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 100:4033–4039. 2002. View Article : Google Scholar : PubMed/NCBI
24	Ley K, Laudanna C, Cybulsky MI and Nourshargh S: Getting to the site of inflammation: The leukocyte adhesion cascade updated. Nat Rev Immunol. 7:678–689. 2007. View Article : Google Scholar : PubMed/NCBI
25	Reiter RA, Varadi K, Turecek PL, Jilma B and Knöbl P: Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation. Thromb Haemost. 93:554–558. 2005. View Article : Google Scholar : PubMed/NCBI
26	Martin K, Borgel D, Lerolle N, Feys HB, Trinquart L, Vanhoorelbeke K, Deckmyn H, Legendre P, Diehl JL and Baruch D: Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med. 35:2375–2382. 2007. View Article : Google Scholar : PubMed/NCBI
27	Cao WJ, Niiya M, Zheng XW, Shang DZ and Zheng XL: Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells. J Thromb Haemost. 6:1233–1235. 2008. View Article : Google Scholar : PubMed/NCBI
28	Ono T, Mimuro J, Madoiwa S, Soejima K, Kashiwakura Y, Ishiwata A, Takano K, Ohmori T and Sakata Y: Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: Its correlation with development of renal failure. Blood. 107:528–534. 2006. View Article : Google Scholar : PubMed/NCBI
29	Biron BM, Ayala A and Lomas-Neira JL: Biomarkers for sepsis: What is and what might be? Biomark Insights. 10 (Suppl 4):7–17. 2015.PubMed/NCBI
30	Pepys MB and Hirschfield GM: C-reactive protein: A critical update. J Clin Invest. 111:1805–1812. 2003. View Article : Google Scholar : PubMed/NCBI
31	Maruna P, Nedelníková K and Gürlich R: Physiology and genetics of procalcitonin. Physiol Res. 49 (Suppl 1):S57–S61. 2000.PubMed/NCBI
32	Becker KL, Snider R and Nylen ES: Procalcitonin assay in systemic inflammation, infection, and sepsis: Clinical utility and limitations. Crit Care Med. 36:941–952. 2008. View Article : Google Scholar : PubMed/NCBI
33	Billeter A, Turina M, Seifert B, Mica L, Stocker R and Keel M: Early serum procalcitonin, interleukin-6, and 24-hour lactate clearance: useful indicators of septic infections in severely traumatized patients. World J Surg. 33:558–566. 2009. View Article : Google Scholar : PubMed/NCBI
34	Brunkhorst FM, Al-Nawas B, Krummenauer F, Forycki ZF and Shah PM: Procalcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia. Clin Microbiol Infect. 8:93–100. 2002. View Article : Google Scholar : PubMed/NCBI
35	Bele N, Darmon M, Coquet I, Feugeas JP, Legriel S, Adaoui N, Schlemmer B and Azoulay E: Diagnostic accuracy of procalcitonin in critically ill immunocompromised patients. BMC Infect Dis. 11:2242011. View Article : Google Scholar : PubMed/NCBI